New DUROLANE Agreement

Bioventus entered into an agreement with Galderma to bring DUROLANE knee osteoarthritis treatment to the U.S., and plans to file a Premarket Approval Application with FDA in early 2017.

Galderma manufactures DUROLANE and other hyaluronic acid products. Bioventus purchased the ex-U.S. assets of DUROLANE in 2014, and has...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0